The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-fluorouracil or cisplatin on gastric cancer cell lines

Cancer Investigation

Volumn 28, Issue 10, 2010, Pages 1038-1047

  Li, Xiao Ling ^a,b   Yi, Shao Qiong ^c   Xu, Jian Ming ^b   Zhang, Yang ^d   Yingying Feng, ^b   Chen, Wei ^c   Song, San Tai ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing 307 Hospital   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

5 Fluorouracil; Cisplatin; Gastric cancer; HER 2 neu; Trastuzumab

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL SEPARATION; CISPLATIN; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENDONUCLEASES; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 78649275624     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.483512     Document Type: Article

References (35)

1. Karpeh, M. S.; Kelsen, D. P.; Tepper, J. E. Cancer of the stomach. In Cancer: Principles and Practice of Oncology. V. T. DeVita, Jr.; S. Hellman; S. A. Rosenberg (eds.). Philadelphia, PA: Lippincott, 2001, 1092-1126.
2. Van Cutsem, E.; Kang, Y.; Chung, H.; Shen, L.; Sawaki, A.; Lordick, F.; Hill J.; Lehle, M.; Feyereislova, A.; Bang, Y. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009, 27, 18s (suppl; abstr LBA4509).
3. Roukos, D. H. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 2009 (Oct. 20). [Epub ahead of print].
4. Gong, S. J.; Jin, C. J.; Rha, S. Y.; Chung, H. C. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 2004, 214 (2), 215-224.
5. Matsui, Y.; Inomata, M.; Tojigamori, M.; Sonoda, K.; Shiraishi, N.; Kitano, S. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005, 27 (3), 681-685.
6. Fujimoto-Ouchi, K.; Sekiguchi, F.; Yasuno, H. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007, 59 (6), 795-805.
7. Kim, S. Y.; Kim, H. P.; Kim, Y. J.; Oh do, Y.; Im, S. A.; Lee, D.; Jong, H. S.; Kim, T. Y.; Bang, Y. J. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008, 32 (1), 89-95.
8. Morelli, M. P.; Cascone, T.; Troiani, T.; De Vita, F.; Orditura, M.; Laus, G.; Eckhardt, S. G.; Pepe, S.; Tortora, G.; Ciardiello, F. Sequencedependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 2005, 16 (Suppl 4), 61-68.
9. Wang, Y.; Peng, D.; Huang, W.; Zhou, X.; Liu, J.; Fang, Y. Mechanism of altered TNF-alpha expression by macrophage and the modulatory effect of Panax notoginseng saponins in scald mice. Burns 2006, 32 (7), 846-852.
10. Xu, J. M.; Paradiso, A.; McLeod, H. L. Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: is there a need for a more rational design? Eur J Cancer 2004, 40 (12), 1807-1809.
11. Baselga, J. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 2004, 22, 759-761.
12. Giaccone, G.; Herbst, R. S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, R. B.; Schiller, J. H.; Von Pawel, J.; Pluzanska, A.; Gatzemeier, U.; Grous, J.; Ochs, J. S.; Averbuch, S. D.; Wolf, M. K.; Rennie, P.; Fandi, A.; Johnson, D. H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22, 777-784.
13. Herbst, R. S.; Giaccone, G.; Schiller, J. H.; Natale, R. B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J. A.; Wolf, M. K.; Krebs, A. D.; Averbuch, S. D.; Ochs, J. S.; Grous, J.; Fandi, A.; Johnson, D. H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22, 785-794.
14. Herbst, R. S.; Prager, D.; Herman, R.; Fehrenbacher, L.; Johnson, B. E.; Sandler, A.; Kris, M. G.; Tran, H. T.; Klein, P.; Li, X.; Ramies, D.; Johnson, D. H.; Miller, V. A.; TRIBUTE Investigator Group. TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). ASCO 2004, 22, 7011.
15. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21, 2237-2246. (Pubitemid 46621858)
16. Kris, M. G.; Natale, R. B.; Herbst, R. S.; Lynch, T. J., Jr.; Prager, D.; Belani, C. P.; Schiller, J. H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K. S.; Cella, D.; Wolf, M. K.; Averbuch, S. D.; Ochs, J. J.; Kay, A. C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 2003, 290, 2149-2158. (Pubitemid 37432975)
17. Perez-Soler, R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small cell lung cancer. Clin Lung Cancer 2004, 6 (Suppl 1), S20-S23.
18. Xu, J. M.; Azzariti, A.; Colucci, G.; Paradiso, A. The effect of gefitinib in combination with oxaliplatin is schedule-dependent in colon cancer lines. Cancer Chemother Pharmacol 2003, 52, 442-448.
19. Azzariti, A.; Xu, J. M.; Porcelli, L.; Paradiso, A. The scheduledependent enhanced cytotoxic activity of 7-ethyl-10-hydroxycamptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol 2004, 68 (1), 135-144.
20. Jackisch, C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 2006, 11, 34-41.
21. Sauter, G.; Lee, J.; Bartlett, J. M.; Slamon, D. J.; Press, M. F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27 (8), 1323-1333.
22. Hudziak, R. M.; Lewis, G. D.; Winget, M.; Fendly, B. M.; Shepard, H. M.; Ullrich, A. P185HER2 monoclonal antibody has antiproliferative effects in vivo and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989, 9 (3), 1165-1172.
23. Goldenberg, M. M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999, 21 (2), 309-318.
24. Chou, T. C. Preclinical versus clinical drug combination studies. Leuk Lymphoma 2008, 49 (11), 2059-2080.
25. Xu, J. M.; Azzariti, A.; Severino, M.; Lu, B.; Colucci, G.; Paradiso, A. Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol 2003, 66 (4), 551-563.
26. Pegram, M. D.; Lopez, A.; Konecny, G.; Slamon, D. J. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000, 27 (6, Suppl 11), 21-25 (discussion 92-100).
27. Fujimoto-Ouchi, K.; Sekiguchi, F.; Tanaka, Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002, 49 (3), 211-216.
28. Nahta, R.; Esteva, F. J. Herceptin: mechanisms of action and resistance. Cancer Lett 2006, 232 (2), 123-138.
29. Knuefermann, C.; Lu, Y.; Liu, B.; Jin, W.; Liang, K.; Wu, L.; Schmidt, M.; Mills, G. B.; Mendelsohn, J.; Fan, Z. HER2/PI-3K/AKT activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22 (21), 3205-3212.
30. Oki, E.; Baba, H.; Tokunaga, E.; Nakamura, T.; Ueda, N.; Futatsugi, M.; Mashino, K.; Yamamoto, M.; Ikebe, M.; Kakeji, Y.; Maehara, Y. AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005, 117 (3), 376-380.
31. Ozes, O. N.; Mayo, L. D.; Gustin, J. A.; Pfeffer, S. R.; Pfeffer, L. M.; Donner, D. B. NF-kB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401 (6748), 82-85.
32. Wang, W.; Cassidy, J. Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br J Cancer 2003, 88 (4), 624-629.
33. Cummings, M.; Higginbottom, K.; McGurk, C. J.; Wong, O. G.; Köberle, B.; Oliver, R. T.; Masters, J. R. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 2006, 72 (2), 166-175.
34. Peters, G. J.; Backus, H. H.; Freemantle, S.; van Triest, B.; Codacci-Pisanelli, G.; Van der Wilt, C. L.; Smid, K.; Lunec, J.; Calvert, A. H.; Marsh, S.; McLeod, H. L.; Bloemena, E.; Meijer, S.; Jansen, G.; van Groeningen, C. J.; Pinedo, H. M. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002, 1587 (2-3), 194-205.
35. Pietras, R. J.; Fendly, B. M.; Chazin, V. R.; Pegram, M. D.; Howell, S. B.; Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9 (7), 1829-1838.